Alcohol use disorder is, at its core, a brain condition. Decades of neuroscience research point to the dopamine system, especially circuits running through a region called the striatum, as a key player in how cravings form and how reinforcing alcohol feels. Disruptions in dopamine receptor availability and release patterns appear repeatedly in studies of people with alcohol use disorder, making those receptors an obvious target for researchers looking for new approaches.
A newly recruiting clinical trial is asking whether tirzepatide, a dual-acting peptide that targets two gut-hormone receptors, might alter those dopamine signals in meaningful ways. The trial uses positron emission tomography combined with functional MRI to watch dopamine activity unfold in living brains, comparing results in healthy volunteers against participants who meet criteria for alcohol use disorder. The aim is not to treat anyone in a clinical sense but to generate precise, mechanistic data about whether and how this peptide changes the brain's reward chemistry.
The trial record, registered under NCT07559500, describes a two-part protocol with a clear hypothesis: tirzepatide will shift the balance between two types of dopamine receptors, dampen dopamine release triggered by a chemical challenge, and reduce the brain's reactivity to cues associated with alcohol and food. Whether those hypotheses hold up is exactly what the research is designed to test.
Background on dopamine and alcohol use disorder
Dopamine is a chemical messenger the brain releases in response to rewarding experiences. Two families of receptors, broadly called D1 and D2, receive those signals and translate them into behavior. Research has consistently found that people with alcohol use disorder tend to have fewer available D2 receptors in the striatum, which is the brain region most associated with reward, motivation, and habit formation. Lower D2 availability is thought to reduce a natural brake on reward-seeking, making alcohol-related cues more compelling and abstinence harder to sustain.
Scientists often probe this system by giving study participants a chemical that causes a controlled spike in dopamine, then measuring how receptors respond using radioactive tracer compounds visible on PET scans. This approach lets researchers quantify receptor availability and dopamine release in a way that self-reports or behavioral tests alone cannot capture. The current trial uses this established methodology as its backbone.
What tirzepatide is and why researchers are interested in it
Tirzepatide is a synthetic peptide that activates receptors for two gut hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Both receptors are found not only in the pancreas and gut but also in regions of the brain involved in appetite regulation and reward processing. That brain distribution is one reason researchers are curious about effects beyond metabolism.
Earlier work with single-target peptides in this hormone class suggested possible effects on alcohol consumption and craving in animal models and some early human observations. Tirzepatide's dual-receptor action makes it an interesting candidate for a more detailed mechanistic investigation. Importantly, the trial is studying the peptide as a research tool to map brain changes, not as an approved or recommended treatment for alcohol use disorder.
Trial design and participant groups
The protocol is divided into two distinct parts. Part 1 enrolls five healthy volunteers and focuses on a methodological question: how reproducible are striatal dopamine measurements when the same scanning procedure is repeated twice in the same person? Establishing that reproducibility is essential before drawing conclusions from any drug-related changes detected in Part 2.
Part 2 enrolls 88 participants split evenly between 44 healthy volunteers and 44 people with alcohol use disorder. Both groups receive two injections one week apart, one containing tirzepatide and one a placebo, in a controlled crossover arrangement. PET imaging with two different radioactive tracers, one that tracks D2 receptors and one that tracks D1 receptors, is paired with functional MRI to capture both receptor availability and blood-flow-based measures of brain reactivity.
The chemical challenge used to provoke dopamine release is intravenous methylphenidate, a compound long used in research settings to reliably elevate dopamine in the striatum. Participants also view curated images of alcoholic beverages and food during scanning, allowing researchers to measure how the brain reacts to those real-world triggers before and after the peptide or placebo.
Primary and secondary measurements
The primary endpoints for Part 2 are changes in D1 and D2 receptor availability in the striatum, the size of the dopamine increase produced by the methylphenidate challenge, and the pattern of brain activation seen during both the chemical challenge and the cue-viewing tasks. These are objective, scanner-derived numbers rather than self-assessments.
Secondary measurements cover a broad range of outcomes that researchers often track in alcohol use disorder research. For participants with the disorder specifically, these include scores on a standardized alcohol craving questionnaire and a clinical alcohol withdrawal assessment. All participants complete measures of food craving, mood using the Profile of Mood States scale, sleep quality through both wrist actigraphy and self-report, and locomotor activity.
Exploratory endpoints add structural brain MRI, resting-state functional MRI, task-based functional MRI, and cognitive performance testing, plus body weight recorded at multiple points. Together these measurements would allow the research team to see whether any dopamine changes correspond to shifts in behavior, cognition, or physical markers.
Study hypotheses and what they would mean
The trial record states three specific hypotheses. First, researchers predict that tirzepatide compared to placebo will increase the availability of D2 receptors while decreasing D1 receptor availability in the striatum. If confirmed, that pattern would suggest the peptide partially reverses the receptor deficit commonly observed in alcohol use disorder.
Second, the team hypothesizes that tirzepatide will blunt the dopamine surge produced by the methylphenidate challenge and reduce overall brain reactivity to that challenge. A smaller dopamine spike in response to a stimulant probe would imply that the peptide is modulating the sensitivity of reward circuitry.
Third, and perhaps most directly relevant to the disorder being studied, researchers predict that tirzepatide will reduce the brain's response to alcohol and food cues more strongly in participants with alcohol use disorder than in healthy controls. A difference between groups rather than a uniform effect in everyone would suggest that the peptide's action is especially relevant when the dopamine system is already dysregulated.
None of these hypotheses are confirmed yet. The trial is actively recruiting, meaning results are not available. The hypotheses represent the scientific reasoning behind the study design, not established findings.
Broader research context
This trial sits within a growing body of work examining whether peptides that act on gut-brain hormone pathways might influence addiction-related neurobiology. Animal studies have pointed toward reductions in voluntary alcohol intake and shifts in reward behavior when these pathways are activated, but translating those findings into a precise mechanistic picture in humans requires exactly the kind of controlled, imaging-heavy approach this trial employs.
The combination of PET and fMRI scanning makes the protocol technically demanding but scientifically informative. PET provides a direct readout of receptor levels and neurotransmitter release, while fMRI captures how different brain areas communicate and activate in real time. Using both in the same participants, and comparing a clinical population against healthy controls, is designed to produce a richer and more interpretable dataset than either method alone could provide.
For the broader research community, the results could help clarify whether the dopamine system is a genuine mediator of any behavioral effects associated with this class of peptides, or whether other pathways carry more of the explanatory weight. That question has implications not just for alcohol use disorder research but for the study of reward and motivation more generally.
